Patients with BRAF V600E-mutant metastatic colorectal cancer experienced poor clinical outcomes with systemic therapy, ...

Patients with BRAF V600E-mutated metastatic colorectal cancer experienced improved responses when treated with Braftovi plus Erbitux and mFOLFOX6.

For patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), encorafenib + cetuximab (EC) plus standard ch ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...

Pfizer's Phase 3 BREAKWATER trial showed Braftovi combo significantly improved PFS and OS in colorectal cancer with BRAF ...

“The BRAFTOVI regimen is emerging as a new standard of care as the first targeted therapy approved for use as early as first-line for patients with mCRC with a BRAF V600E mutation. We look ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the ...

The BRAF Inhibitors market is expected to grow significantly in the coming years. This is due to the increasing number of patients being diagnosed with cancer, rise in biomarker testing rates, the ...

Pfizer’s metastatic colorectal cancer (mCRC) combination therapy has met one of the primary endpoints of improving ...

Pfizer has announced that its Braftovi (encorafenib) regimen significantly improved both progression-free and overall ...